MerckMRK
NYSEPharmaceuticals
No cached AI snapshot yet for MRK.
Be the first to run a multi-agent analysis on this ticker.
Key Stats
75,000 employees2.47B shares outstandingdividend yield 3.09%
Next earnings ~May 5, 2026 · Ex-dividend Mar 16, 2026 · Dividend $0.85 quarterly
About Merck
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).
Latest News
Merck beats earnings estimates as cancer drug Keytruda sales surged 12%
Merck Q1 earnings beat lifts shares; 2026 guidance narrowed
Merck in charts: KEYTRUDA +11.5% Y/Y in Q1; Gardasil -19%, Januvia -28%
Earnings Snapshot: Merck FY outlook misses estimate; guidance excludes Terns deal, flags $5.8B charge
Merck posts quarterly loss due to Cidara charge, sales rise 5%
Merck beats top-line and bottom-line estimates; narrows FY26 outlook
Related Stocksin Pharmaceuticals
Ready to see the live AI view on MRK?
Launch a real-time multi-agent room — Claude, GPT, Gemini, DeepSeek, Grok, and Qwen analyzing MRK side-by-side with live signals.